Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia

International Journal of Neuropsychopharmacology

Volumn 17, Issue 3, 2014, Pages 485-490

  Srisawat, Umarat ^a   Reynolds, Gavin P ^a   Zhang, Zhi Jun ^b   Zhang, Xiang Rong ^b   Arranz, Belen ^c   San, Luis ^c   Dalton, Caroline F ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antipsychotic; Genotype; MTHFR polymorphism; Schizophrenia; Weight gain

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

5 HT2C RECEPTOR GENE; ADULT; ALLELE; ARTICLE; BODY MASS; CAUCASIAN; CHINESE; FEMALE; GENE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CHINA; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; EPISTASIS, GENETIC; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SPAIN; WEIGHT GAIN; YOUNG ADULT;

EID: 84897901955     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001375     Document Type: Article

References (25)

1. Burghardt KJ, Pilsner JR, Bly MJ, Ellingrod VL (2012) DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences. Epigenomics 4:261-268.
2. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 (Suppl. 7):4-18.
3. Chen AR, Zhang HG, Wang ZP (2010) C-reactive protein, vitamin B12 and C677T polymorphism of N-5,10-methylenetetrahydrofolate reductase gene are related to insulin resistance and risk factors for metabolic syndrome in Chinese population. Clin Invest Med 33:E290-E297.
4. De Hert M, Schreurs V, Vancampfort D, van Winkel R (2009) Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8:15-22.
5. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J (2008) Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 98:47-54.
6. Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zöllner SK, Pop-Busui R (2012) Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol 32:261-265.
7. Friso S, Choi SW (2002) Gene-nutrient interactions and DNA methylation. J Nutr 132 (Suppl. 8):2382S-2387S.
8. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, Olivieri O, Jacques PF, Rosenberg IH, Corrocher R, Selhub J (2002) A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 99:5606-5611.
9. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975-981.
10. Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease susceptibility. Nat Rev Genet 8:253-262.
11. Kuzman MR, Müller DJ (2012) Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia. Pharmacogenomics 13:843-846.
12. Lewis SJ, Lawlor DA, Davey Smith G, Araya R, Timpson N, Day IN, Ebrahim S (2006) The thermolabile variant of MTHFR is associated with depression in the BritishWomen's Heart and Health Study and a meta-analysis. Mol Psychiatry 11:352-360.
13. Lunegova OS, Kerimkulova AS, Turdakmatov NB, Sovkhozova NA, Nabiev MP, Isakova ZhT, Iusupova ÉU, Moldokeeva ChB, Gotfrid IIu, Mirrakhimov AÉ, Aldasheva NM, Kheǐer E, Aldashev AA, Mirrakhimov ÉM (2011) Association of C677T gene polymorphism of methylenetetrahydrofolate reductase with insulin resistance among Kirghizes. Kardiologiia 51:58-62.
14. Reynolds GP (2012) Pharmacogenetic aspects of antipsychotic drug-induced weight gain: a critical review. Clin Psychopharmacol Neurosci 10:71-77.
15. Reynolds GP, Zhang ZJ, Zhang XB (2002) Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359:2086-2087.
16. Reynolds GP, Yevtushenko OO, Gordon S, Arranz B, San L, Cooper SJ (2013) The obesity risk gene FTO influences bodymass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. Int J Neuropsychopharmacol 16:1421-1425.
17. Stern LL, Mason JB, Selhub J, Choi SW (2000) Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 9:849-853.
18. Sugden C (2006) One-carbon metabolism in psychiatric illness. Nutr Res Rev 19:117-136.
19. Templeman LA, Reynolds GP, Arranz B, San L (2005) Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15:195-200.
20. Terruzzi I, Senesi P, Fermo I, Lattuada G, Luzi L (2007) Are genetic variants of the methyl group metabolism enzymes risk factors predisposing to obesity? J Endocrinol Invest 30:747-753.
21. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22:195-201.
22. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M (2010a) MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 121:193-198.
23. van Winkel R, Moons T, Peerbooms O, Rutten B, Peuskens J, Claes S, van Os J, De Hert M (2010b) MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int Clin Psychopharmacol 25:270-276.
24. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172.
25. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184:58-62.